Clinical trial
Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration
NCT03261635 is registered in ClinicalTrials.gov with Università degli Studi di Brescia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration
- Lead sponsor
- Università degli Studi di Brescia
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 7, 2016
- Completion date
- July 25, 2017
- Enrollment
- 58 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.